Viking Therapeutics' Weight-Loss Drug Trial Results Double Stock

Viking Therapeutics, a San Diego-based company, has announced promising results for its new weight loss drug, a GLP-1 drug similar to Ozempic, with users achieving an average 14% weight loss from baseline numbers after 13 weeks of treatment. This news has caused a surge in Viking Therapeutics' stock value as investors seek a cheaper path into the weight loss drug market currently dominated by Novo Nordisk and Eli Lilly. Other pharmaceutical companies like Regeneron, Amgen, and Zealand Pharma are also developing weight loss drugs to capture some of the market share held by the two giants. Zealand Pharma's stock soared after announcing strong results in a clinical trial for a liver disease drug that is also being tested for weight loss.